Therefore, COVID-19 patients with cancer manifest lower levels of IFN-I and IFN-III, moderate IFN stimulated genes, and proinflammatory cytokine production, which indicates decreased antiviral immune function (Perico et al., 2021[57]). This evidence concerns the gene IFNA1 and cancer.